Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Top-line results from Exelixis' cabozantinib phase 3 trial on medullary thyroid cancer

Exelixis, Inc. today reported top-line results from the ongoing phase 3 clinical trial of cabozantinib in patients with advanced medullary thyroid cancer (MTC), known as the EXAM trial.

24 Oct 2011

PSA test predicts biopsy need and prostate cancer development

The prostate-specific antigen test, commonly known as the PSA test, is valuable in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer, a Mayo Clinic study has found. The findings were released today during a meeting of the North Central Section of the American Urological Association in Rancho Mirage, Calif.

22 Oct 2011

New mathematical models can predict prostate cancer aggressiveness

Alexander R. A. Anderson, Ph.D., co-director of Integrative Mathematical Oncology (IMO) at Moffitt Cancer Center, and his colleagues, Simon Hayward, Ph.D., at Vanderbilt University and Gustavo Ayala, M.D., at Baylor College of Medicine, have received a five-year, $3 million grant from the National Institutes of Health to create new mathematical models to predict prostate cancer aggressiveness.

22 Oct 2011

Learning about politics in the midst of screening recommendations

The recent recommendation by the U.S. Preventive Services Task Force that women get less frequent screenings for cervical cancer demonstrated a remarkably different response than other such recommendations.

22 Oct 2011

C-11 choline PET/CT scans can be utilized as prostate cancer staging tool

Recent studies have suggested that C-11 choline positron emission tomography/computerized tomography (PET/CT) scans can be utilized as a staging and potentially therapeutic tool in prostate cancer.

22 Oct 2011

AAHPO honors BMC physician for medical contributions in the U.S., Armenia

Richard Babayan, MD, was honored recently by the Armenian American Health Professional Organization (AAHPO) for his exceptional contributions to medicine in both the United States and in Armenia.

21 Oct 2011

TJUH offers new optical imaging agent for bladder cancer detection

Thomas Jefferson University Hospital is one of a select number of medical centers nationwide—and currently the only one in the Northeast—offering a newly approved optical imaging agent for the detection of papillary cancer of the bladder in patients with known or suspected bladder cancer.

21 Oct 2011

OncoGenex commences enrollment in OGX-427 Phase II trial for bladder cancer

OncoGenex Pharmaceuticals, Inc. announced today that it has initiated patient enrollment in a randomized, Phase II clinical trial evaluating OGX-427, an inhibitor of heat shock protein 27 (Hsp27), in patients with advanced bladder cancer.

21 Oct 2011

Older men more likely to die from prostrate cancer

Contrary to common belief, men age 75 and older are diagnosed with late-stage and more aggressive prostate cancer and thus die from the disease more often than younger men, according to a University of Rochester analysis published online this week by the journal, Cancer.

20 Oct 2011

Experts recommending fewer cancer screenings

New cervical cancer screening guidelines are the latest example of this emerging cautious view.

20 Oct 2011

First Edition: October 19, 2011

Now on Kaiser Health News' blog, Capsules, Marilyn Werber Serafini reports: "Medicare might fare better than other health care programs if the congressional super committee fails to agree on a deficit-reduction package and automatic cuts kick in, but even 2 percent is a big problem when it comes on top of other recent hits, warn Rick Pollack, executive vice president of the American Hospital Association, and Karen Ignagni, president of America's Health Insurance Plans."

19 Oct 2011

Comprehensive roadmap promises to improve cancer immunotherapy development

The Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute (CRI) and the Association for Cancer Immunotherapy (CIMT) have issued a joint white paper, published in the October 13 issue of Nature Biotechnology, outlining a comprehensive roadmap that promises to help improve and facilitate the path forward in the development of novel immunotherapies for cancer.

19 Oct 2011

Oral laquinimod shows promise against multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced the presentation of Phase III clinical and pre-clinical data, which collectively demonstrate that once-daily oral laquinimod modulates the pathological processes of multiple sclerosis to impact disease activity, disability progression and brain volume loss.

19 Oct 2011

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010. Operational results increased 2.6% and the positive impact of currency was 4.2%. Domestic sales declined 3.7%.

18 Oct 2011

AR gene has opposite effects on prostate and breast cancers

Researchers at Cleveland Clinic have discovered that a gene - known as an androgen receptor (AR) - is found in both prostate and breast cancers yet has opposite effects on these diseases.

18 Oct 2011

AICR recommends intake of cancer-fighting foods

Colleen Spees has always been interested in the role that diet played in disease, and set her sights on a career where she would counsel patients and train future dietitians. With multiple family members diagnosed with various types of cancer, Colleen decided to make the transition from clinical professional and nutrition educator to research scientist.

18 Oct 2011

Dendreon initiates enrollment in DN24-02 Phase 2 trial for HER2 positive cancer

Dendreon Corporation today announced that the company has begun enrolling patients into a Phase 2 trial for DN24-02, Dendreon's investigational active cellular immunotherapy being evaluated for the treatment of HER2 positive cancer.

18 Oct 2011

Viewpoints: Class Act's effect on health law; new prescriptions for Medicare; food marketing to kids

Now that one of ObamaCare's major new benefit programs has been scrapped, liberals are trying to make stone soup by claiming that the Obama Administration merely committed an act of "good government." They claim that when this long-term care insurance program proved to be unworkable, the Administration conceded as much, and now it's gone. So let's review the evidence, not least because it so perfectly illustrates the recklessness that produced the Affordable Care Act.

18 Oct 2011

Six new Bristol-Myers Squibb grants to reduce cancer disparities in CEE

The Bristol-Myers Squibb Foundation today announced six new grants totaling more than $900,000 that focus on improving cancer awareness, prevention and care by developing cancer nursing skills and building nurse-community partnerships in Hungary, Poland, Romania and Russia.

15 Oct 2011

Janssen, BeiGene enter in-licensing agreement for two clinical-stage oncology compounds

BeiGene, Ltd., today announced that it has entered into exclusive in-licensing and co-development agreements with Janssen Pharmaceutica NV and its affiliates for two clinical-stage oncology compounds.

15 Oct 2011